drugset / Trial / NCT06373081
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
Timeline
- Start
- 2024-04-20
- Primary completion
- 2025-04-15
- Completion
- 2026-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD19-CD3E-CAR-T cells | Cell therapy | — | Intravenous |